197 related articles for article (PubMed ID: 25001536)
1. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL).
Fulda S
Adv Exp Med Biol; 2014; 818():167-80. PubMed ID: 25001536
[TBL] [Abstract][Full Text] [Related]
2. From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
Cordier SM; Papenfuss K; Walczak H
Results Probl Cell Differ; 2009; 49():115-43. PubMed ID: 19142621
[TBL] [Abstract][Full Text] [Related]
3. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of TRAIL receptor agonists in cancer treatment.
Fulda S
Eur J Clin Pharmacol; 2015 May; 71(5):525-7. PubMed ID: 25704217
[TBL] [Abstract][Full Text] [Related]
5. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling.
Thorburn A
J Thorac Oncol; 2007 Jun; 2(6):461-5. PubMed ID: 17545839
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
[TBL] [Abstract][Full Text] [Related]
8. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
9. The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs.
Wang F; Lin J; Xu R
Curr Pharm Des; 2014; 20(42):6714-22. PubMed ID: 25269558
[TBL] [Abstract][Full Text] [Related]
10. Modulation of TRAIL signaling for cancer therapy.
Fulda S; Debatin KM
Vitam Horm; 2004; 67():275-90. PubMed ID: 15110182
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Elias A; Siegelin MD; Steinmüller A; von Deimling A; Lass U; Korn B; Mueller W
Clin Cancer Res; 2009 Sep; 15(17):5457-65. PubMed ID: 19706813
[TBL] [Abstract][Full Text] [Related]
12. The TRAIL of oncogenes to apoptosis.
Oikonomou E; Pintzas A
Biofactors; 2013; 39(4):343-54. PubMed ID: 23813857
[TBL] [Abstract][Full Text] [Related]
13. TRAIL and cancer therapy.
Kruyt FA
Cancer Lett; 2008 May; 263(1):14-25. PubMed ID: 18329793
[TBL] [Abstract][Full Text] [Related]
14. Targeting death receptors to fight cancer: from biological rational to clinical implementation.
Mocellin S
Curr Med Chem; 2010; 17(25):2713-28. PubMed ID: 20586721
[TBL] [Abstract][Full Text] [Related]
15. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
Johnstone RW; Frew AJ; Smyth MJ
Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
[TBL] [Abstract][Full Text] [Related]
17. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells.
Lippa MS; Strockbine LD; Le TT; Branstetter DG; Strathdee CA; Holland PM
Apoptosis; 2007 Aug; 12(8):1465-78. PubMed ID: 17440816
[TBL] [Abstract][Full Text] [Related]
18. The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).
Mellier G; Pervaiz S
Free Radic Res; 2012 Aug; 46(8):996-1003. PubMed ID: 22559302
[TBL] [Abstract][Full Text] [Related]
19. [Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand].
Yao GH; Hou YY
Wei Sheng Yan Jiu; 2006 Jan; 35(1):115-7. PubMed ID: 16598953
[TBL] [Abstract][Full Text] [Related]
20. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
